Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.01

€1.01

1.110%
0.011
1.110%
-
 
11.12.25 / Frankfurt WKN: A41QA9 / Name: Lir Life Sciences Corp. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Lir Life Sciences Corp. Stock

There is an upward development for Lir Life Sciences Corp. compared to yesterday, with an increase of €0.011 (1.110%).

Pros and Cons of Lir Life Sciences Corp. in the next few years

Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

Vancouver, Canada – December 11, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent

Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies

Vancouver, Canada – December 10, 2025 – Lir Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative